Table 2.

Novel therapeutic strategies that attenuate CV calcification in non-transgenic animal CKD models.

Treatment	Substance	Dosis	Application	Experimental Model	Species, Strain	Ref.
Bisphospho-nate	Etidronate	5 or 10 mg/kg	s.c., daily, 3 weeks	5/6 nephrectomy	Wistar rat	[54]
Vitamin K	Mena-quinone-7	50 µg/kg	Oral gavage, daily 4 weeks	Adenine diet	Sprague-Dawley rat	[66]
Omega-3 fatty acid	Eicosapenta-enoic acid	300 mg/kg	Oral gavage, daily 4 weeks	Adenine diet	Sprague-Dawley rat	[66]
Vitamin D receptor agonist	Calcitriol Paricalcitol	30 ng/kg 100 or 300 ng/kg	i.p., 3 times/week, 3 weeks	5/6 nephrectomy	DBA/2J mouse	[26]
Dietary supplement	Magnesium	0.1–1.1%	Food intake, 14 days	5/6 nephrectomy	Wistar rat	[67]
Dietary supplement	Magnesium	3%	Food intake, 7 weeks	5/6 nephrectomy	Non-agouti mouse	[68]
Hexasodium salt	SNF472	50 mg/kg	i.v., daily, 19 days	Adenine diet	Wistar rat	[20]

S.c: subcutaneous; i.p.: intraperitoneal; i.v.: intravenous; Ref: Reference.